Study for People Enrolled in the New York State Multiple Sclerosis Consortium
Protocol: STUDY00004395
Full Title
Evaluation of Patient-Reported Outcomes Associated with Natalizumab Use in a Real-World Setting
Description
This study enrolls people with Multiple Sclerosis who have already enrolled in the New York State Multiple Sclerosis Consortium (NYSMSC). The purpose of this study is to learn more about the experiences of people with MS who are having a natalizumab infusion.

This study involves a one-time survey. Participants will be NYSMSC members who are having natalizumab infusion at the Jacobs MS Center for Treatment and Research. Study takes place at UB's downtown campus.

Technical Description

To evaluate the association between fatigue and other patient-reported outcomes with natalizumab use in multiple sclerosis patients in the New York State Multiple Sclerosis Consortium
Compensation: No
Eligibility
Adults ages 18+.
Have multiple sclerosis.
Are enrolled in the New York State Multiple Sclerosis Consortium (NYSMSC),
Have taken natalizumab for the treatment of MS for at least six months.
Age Group: Adults
Principal Investigator: CAILA VAUGHN
Contact(s)
CAILA VAUGHN
hilbert2@buffalo.edu
+1 716-859-3393
Want to Learn More?
Enrollment Update

Due to COVID-19, new enrollment in research studies will be greatly limited. If you are interested in a study, there may be a longer waiting period to receive a response to your inquiry. View the guidance for research participants for additional information.

Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email ctsiresearch@buffalo.edu and someone will assist you.